We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Image-Recognition Program Reads Echocardiograms Faster, Cuts Results Wait Time

By HospiMedica International staff writers
Posted on 20 Nov 2024

An echocardiogram is a diagnostic imaging tool that provides valuable insights into heart structure and function, helping doctors to identify and treat various heart conditions. More...

Now, a new study suggests that integrating an artificial intelligence (AI) program to analyze echocardiograms could reduce the time it takes to receive results, ultimately enabling more timely medical interventions.

In this study, researchers at Yale School of Medicine (New Haven, CT, USA) tested the ability of an AI program called PanEcho to interpret echocardiography videos independently. PanEcho expands on earlier AI applications in cardiology, which were typically limited to analyzing single heart views or focusing on specific disease indicators. The team developed a novel AI system capable of providing comprehensive reports on all major findings from any set of echocardiographic videos. To assess PanEcho's diagnostic performance, the researchers used a standard accuracy measure known as the area under the receiver operating characteristic curve (AUC).

The results showed that when PanEcho was evaluated across 18 diagnostic classification tasks, its average score was 0.91. Additionally, the program was tested for its ability to predict continuous echocardiographic parameters, using mean absolute error, which measures the average difference between predicted and actual values. Smaller differences indicate higher accuracy. In 21 tasks, PanEcho achieved a median normalized mean absolute error of 0.13. The AI system also demonstrated precision in quantifying left ventricle dimensions and function. For instance, when estimating the left ventricle ejection fraction, it showed a mean absolute error of 4.4%, 1.3 mm for intraventricular septum thickness, and 1.2 mm for posterior wall thickness. These measurements are essential for accurately evaluating left ventricular health, a key component of overall heart function. The next step for this AI system, according to the researchers, is to validate its performance in real-world clinical settings, which would provide further insights into its potential for everyday patient care.

“PanEcho has the potential to be used in simplified, AI-assisted screening echocardiograms,” said Gregory Holste, M.S.E., a researcher with the Cardiovascular Data Science (CarDS) Lab at the Yale School of Medicine. “In settings where expert readers may not be readily accessible, PanEcho could rapidly rule out abnormalities that would otherwise require urgent referral.”


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
12-Channel ECG
CM1200B
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Radiofrequency Generator
GX1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.